Breaking News, Collaborations & Alliances

TG, Rhizen in Global Development Pact

To develop PI3K delta inhibitor

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

TG Therapeutics and Rhizen Pharmaceuticals have entered into an exclusive global agreement for the development and commercialization of Rhizen’s lead product candidate, TGR-1202, a PI3K delta inhibitor. The companies will jointly develop the product on a worldwide basis, excluding India, initially focusing on hematologic malignancies and autoimmune disease. Beyond TGR-1202, Rhizen will contribute backup molecules for TG to develop differentiated therapies against these diseases.   TG will ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters